Aglaya

Quick links to important sections

Aglaya

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aglaya

Property Description
Active Ingredients Ethinylestradiol, Norgestimate
Form Oral Tablet
Pharmacological Class Systemic Hormonal Contraceptive
Common Use Prevention of Pregnancy
Origin Synthetic Hormones

Aglaya: Definition, Type, and Class

Aglaya is an Oral Tablet that is categorized as a Combined Oral Contraceptive (COC), placing it within the larger pharmacological group of Systemic Hormonal Contraceptives. This product is a combination of two distinct, synthetic hormone components—an estrogen and a progestin—and is delivered via the oral route. While "Aglaya" is a specific trade name, its core combination of Ethinylestradiol and Norgestimate is found in many widely prescribed generic and branded products globally, utilizing the same dual-hormone strategy. This combination approach is clinically recognized for providing consistent contraceptive protection when used correctly.

Active Ingredients and Combination Composition

The active chemical substances in the medicine are Ethinylestradiol and Norgestimate. Ethinylestradiol serves as the estrogen component, and Norgestimate acts as a prodrug, which is metabolized in the body into its primary active progestin forms, Norelgestromin and Norgestrel. The specific use of Norgestimate is a key feature, differentiating it within the class of COCs that utilize various other progestins. This specific combination of a synthetic estrogen and progestin ensures the hormonal stability required to reliably regulate the reproductive cycle.

Primary Purpose and General Benefit

The main purpose of this combination medication is the prevention of pregnancy in females of reproductive potential. This contraceptive use is the foundational goal, supported by pharmacological studies that establish its efficacy. Beyond preventing conception, the hormonal balance supplied by the product is also utilized to achieve specific therapeutic outcomes. A frequent secondary general use involves the management of moderate acne vulgaris in appropriate female patients who have achieved menarche, demonstrating the medication's dual benefit beyond its primary contraceptive function.

Regulatory References

  1. Oral Contraceptive Pills - StatPearls
  2. Ethinyl Estradiol and Norgestimate Drug Information
  3. Norgestimate and Ethinyl Estradiol Tablets Label

What side effects are possible with Aglaya?

Possible Side Effects and Safety Information

The safety profile of combined oral contraceptives (COCs) containing Ethinylestradiol and Norgestimate (Aglaya) is based on classifications from official regulatory documents. Adverse reactions are grouped by the affected System-Organ Class (SOC) and frequency.

Adverse Reaction Classifications

Frequency Category Representative Adverse Reactions
Very Common (ge 1/10) Headache, breakthrough bleeding, spotting
Common (ge 1/100 to <1/10) Nausea, abdominal pain, breast pain, mood altered, weight gain

Common effects frequently involve the Gastrointestinal, Nervous System, and Reproductive System and Breast Disorders. Irregular bleeding is most common during the first few months of treatment and often resolves with continued use.

Serious Adverse Reactions and Safety Constraints

Regulatory labels mandate explicit warnings for serious, rare adverse reactions, primarily associated with the Vascular Disorders SOC. These include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Arterial Thromboembolism (ATE), such as Stroke and Myocardial Infarction. The risk of VTE is documented as being highest during the first year of initial use.

Other serious documented risks include Hypertension (raised blood pressure) and rare instances of Hepatic Neoplasia (benign liver tumours).

Use is officially contraindicated in women with a current or past history of these vascular disorders, uncontrolled hypertension, or severe liver disease. For non-breastfeeding women, the medication should not be started earlier than four weeks after delivery due to heightened VTE risk.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scope

The official regulatory profile indicates that an acute overdose of Aglaya (Ethinylestradiol/Norgestimate) is not likely to be life-threatening. Ingestion by children typically results in minor, self-limited effects.

Documented Overdose Presentations:

  • The most commonly reported acute manifestations are nausea and vomiting.
  • A delayed gynecological effect may include withdrawal bleeding (heavy vaginal bleeding), typically occurring several days after the ingestion.
  • Other documented signs can include breast tenderness, headache, drowsiness, and emotional changes.

Emergency-Response Statements

When immediate medical help is required (label-derived phrasing only):

  • Seek medical help right away upon suspected overdose. Contacting Poison Control or emergency services is mandated for immediate guidance.
  • Urgent medical attention must be sought immediately if severe symptoms occur, such as signs of a thrombotic event (e.g., sudden severe headache, sudden unexplained shortness of breath, chest pain, or sudden vision loss).

Supportive and Monitoring Measures

  • Treatment is described as symptomatic and supportive, as no specific antidote is known for this combination.
  • If a hospital visit is required, monitoring of vital signs and laboratory tests may be implemented.

Connection to the overall overdose profile Regulatory guidance defines the overdose profile primarily by its low acute toxicity and predictable manifestations. However, the profile simultaneously mandates immediate emergency action for severe symptoms, particularly those related to vascular risks associated with combined hormonal contraceptives.

Therapeutic Uses of Aglaya

The primary function of Aglaya, containing Ethinylestradiol and Norgestimate, is to provide core therapeutic support across two main clinical domains: contraception and the symptomatic management of specific, hormonally influenced conditions. It is commonly used across various contexts requiring consistent cycle control and targeted relief.

Aglaya is applied in situations involving certain distressing symptoms, such as painful periods (dysmenorrhea), excessive menstrual bleeding (menorrhagia), and symptoms related to moderate acne vulgaris. This dual approach means the medication plays a role in managing symptoms that may create noticeable interference with daily comfort, while also assisting with the clinical need for supportive pregnancy planning. It is relevant in contexts requiring ongoing, supportive reproductive planning and for conditions where symptoms may intensify temporarily, such as during the menstrual cycle.

“The support provided helps ease the overall symptom burden, contributing to easing the impact of symptoms on routine activities.”

Quick Fact: Supportive Management of Cyclical Discomfort Aglaya is relevant for easing symptoms related to physical discomfort and systemic imbalance that are characteristic of the menstrual cycle, often used during phases when symptoms become more noticeable. This contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information on Ethinyl Estradiol and Norgestimate

Eligibility and Restrictions for Use

Aglaya (Ethinylestradiol and Norgestimate) is an oral contraceptive officially approved for use in females of reproductive potential. For conditions such as moderate acne, use is established in females at least 15 years of age who have achieved menarche. The medicine is not indicated for use in pre-menarcheal females or the postmenopausal population.


Absolute Contraindications

Aglaya must not be used by individuals with certain pre-existing conditions, primarily those increasing the risk of blood clots or linked to hormone-sensitive tumors. Use is contraindicated if a woman:

  • Smokes and is over age 35.
  • Has a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), stroke, or Coronary Artery Disease.
  • Has Migraine with aura or any migraine headache if over age 35.
  • Has a current or history of Breast Cancer or other hormone-sensitive tumors.
  • Has severe/active liver disease or liver tumors.
  • Has uncontrolled hypertension or diabetes with vascular disease.
  • Is known to be or suspected to be pregnant.

Eligibility Restrictions

Use is not recommended during lactation (breastfeeding). Additionally, the medicine must be discontinued before and after periods of major surgery or prolonged immobilization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction patterns for Aglaya (Ethinylestradiol/Norgestimate), derived strictly from government regulatory documents.

Interaction Classifications

Classification Interacting Substances (Examples) Official Outcome/Restriction
Contraindicated Ombitasvir/paritaprevir/ritonavir, with or without dasabuvir Strictly prohibited due to risk of significant Ethinyl Estradiol exposure increase and toxicity.
Reduced Exposure Enzyme Inducers (e.g., CYP3A4 inducers, St. John's wort) Decreases plasma concentrations of hormonal components, which may reduce contraceptive effectiveness.
Absorption Interaction Bile acid sequestrants (e.g., Colesevelam) Decreases the Area Under the Curve (AUC) of Ethinyl Estradiol.

Official Regulatory Statements

Co-administration with CYP3A4 enzyme-inducing drugs or herbal products (such as St. John's wort) decreases the concentration of the active hormones. This interaction results in a reduction of the contraceptive's efficacy as documented in prescribing information. The interaction with Colesevelam necessitates a procedural separation; the products must be administered 4 hours apart to mitigate the reduction in hormonal exposure. Furthermore, the contraceptive components themselves cause pharmacodynamic alterations by officially raising the serum concentrations of binding globulins and decreasing the body's glucose tolerance.

Mechanism of Action

How Aglaya Works

The mechanism of action for Aglaya (Ethinylestradiol and Norgestimate) involves a combination of central and peripheral biological actions through agonism at steroid hormone receptors.


Central Suppression of the HPO Axis

This domain covers the primary mechanism, where the synthetic hormones act as agonists on the Estrogen and Progesterone Receptors ( ER/ PR) in the hypothalamus and pituitary gland. This action imposes a continuous negative feedback signal, suppressing the LH surge and FSH peaks required for follicular development and ovulation. The resulting physiological effect is functional ovarian quiescence—the ovary fails to release an egg.


Peripheral Barrier and Endometrial Modification

The Progesterone Receptor ( PR) agonism in the lower reproductive tract triggers two secondary effects. First, it alters the cervical glands, leading to the rapid formation of a highly viscous cervical mucus that restricts sperm migration. Second, it modifies the uterine lining, resulting in endometrial atrophy that reduces tissue receptivity. These peripheral changes establish a physical and biological barrier.


Systemic Modulation of Free Androgen Levels

This separate mechanism is driven by the estrogen component, Ethinylestradiol, which enhances hepatic synthesis of Sex Hormone-Binding Globulin ( SHBG). SHBG is a transport protein that binds tightly to androgens (like testosterone) in the bloodstream, lowering the concentration of biologically active free androgens available to tissues throughout the body.

Dosage and Administration Information

How to Use Aglaya

Aglaya (Norgestimate and Ethinyl Estradiol) is administered exclusively via the oral route as a tablet. The primary instruction for use is to take one tablet daily at the same time every day for 28 consecutive days, a schedule critical for maintaining the intended hormonal levels. Administration consistency is emphasized over meal timing, as the tablets may be taken with or without food.


Official Administration Schedule

The full regimen is structured as a 28-day cycle composed of 21 active tablets containing the hormones and 7 inert tablets without hormones. Users must follow the sequential order designated on the blister pack, ensuring the active tablets are taken first. Each subsequent pack is to be started immediately after the last inert tablet of the previous pack.


Use Initiation and Special Conditions

Official labeling describes two methods for initiating the first cycle: the Day 1 Start (beginning on the first day of menses) or the Sunday Start (beginning on the first Sunday after menses onset). When employing the Sunday Start method, an additional non-hormonal contraceptive method must be used for the first seven days of the first cycle to ensure effective coverage.

For the secondary approved indication of moderate acne, the regimen also requires one tablet daily, but its use is specified only for females who have achieved menarche and are at least 15 years of age. Official protocols also detail specific instructions for managing a missed dose, which may necessitate the temporary use of back-up contraception depending on the week the tablet was missed.

Recent Clinical Evidence

Research evidence / Overview of Studies for Aglaya (Ethinylestradiol/Norgestimate)


Evidence for Use in Prevention of Pregnancy (Contraception)

Research into Aglaya's primary use is based on large-scale clinical trials observing healthy women of reproductive age. These studies focus on evaluating outcomes related to the prevention of pregnancy. Findings describe measurements related to expected efficacy outcomes, tracked using standardized metrics like the Pearl Index. Patterns related to the establishment of a regular bleeding schedule were also monitored. Study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.


Evidence for Use in Moderate Acne Vulgaris

Aglaya was studied for its use in patients with moderate acne, based on randomized, double-blind, placebo-controlled trials. These trials monitored outcomes linked to inflammatory or irritative states, tracking changes in lesion counts and overall skin appearance. Trial findings described patterns related to changes in lesion counts when compared against the placebo group after defined time intervals, typically six months. A limitation of this research is that follow-up durations were often limited, meaning there is limited information for long-term outcomes related to the originally tracked measures.


Evidence for Management of Menstrual Cycle-Related Symptoms

Aglaya was evaluated in studies examining patient-reported experiences related to menstrual cycles. Research explored outcomes related to physical discomfort (dysmenorrhea) and episodic changes like unexpected bleeding. Findings describe patterns related to cycle regularity and frequency of unscheduled bleeding in the observed populations. Evidence quality varies across studies, and the effect on every type of menstrual symptom has not been uniformly or extensively studied.


Research Gaps and Follow-up

Data for certain groups remain insufficient, particularly those outside the primary study populations, such as women in older reproductive age groups or individuals with certain comorbid conditions. Long-term effects are not fully established beyond the typical follow-up periods of the initial trials. Certainty remains low regarding the full range of long-term outcomes monitored in studies, and comparative evidence is lacking to definitively compare Aglaya against every other available contraceptive option for every possible outcome.

Frequently Asked Questions (FAQ)

Common questions about Aglaya (FAQ)


Q: What are the main conditions Aglaya is prescribed to manage?

According to the official product information, Aglaya is prescribed to manage two main conditions. Its primary approved indication is for the prevention of pregnancy. It is also indicated for the treatment of moderate acne vulgaris in specific female patients.


Q: Is Aglaya used for short-term or long-term treatment?

Combination oral contraceptives are typically used as a continuous, long-term method of contraception. Official studies reviewed for this drug have examined users for periods exceeding 8 years to monitor potential risks.


Q: Does Aglaya require a special prescription or monitoring?

Aglaya is a prescription medication. Official prescribing information notes that a patient’s progress and effects are typically checked at regular medical visits. This routine monitoring may involve checking a patient's blood pressure and addressing any known side effects.


Q: How is the purpose of Aglaya summarized in official documents?

The official documentation summarizes the drug's purpose as preventing pregnancy. The core mechanism is the suppression of gonadotropins, which leads to the inhibition of ovulation (the release of an egg).


Q: Are there any major risks listed for Aglaya?

Major risks listed in official warnings are related to the increased chance of serious cardiovascular events. These risks include the potential for blood clots (deep vein thrombosis, pulmonary embolism), stroke, and heart attack.


Q: What is the difference between common and serious side effects of Aglaya?

Official labeling separates side effects into two categories. Serious side effects include rare, high-risk events like blood clots, liver problems, or stroke. Common adverse reactions include frequently reported but less severe issues such as headache, nausea, and breast tenderness.


Q: Can Aglaya cause long-term side effects?

Official warnings indicate that studies have shown an association with an increased risk of developing hepatocellular carcinoma (a type of liver tumor) in long-term users, specifically those who have used the drug for periods greater than 8 years.


Q: Do side effects from Aglaya usually go away over time?

Certain common side effects, such as spotting or irregular bleeding, are frequently experienced when first starting the medication. Official information states that these effects have been observed to often improve or resolve over the first few months of use.


Q: Is weight change a known side effect of Aglaya?

Yes, weight fluctuation (either an increase or decrease) and fluid retention are reported as common side effects of Aglaya based on data from clinical trials.


Q: Is Aglaya linked to mood changes or mental health side effects?

Depression, mood altered, and nervousness are listed as reported adverse reactions. Official warnings note that careful observation is warranted for patients with a history of depression while the medication is being used.


Q: What are the signs of a severe allergic reaction to Aglaya?

Signs of a potentially severe allergic reaction listed in regulatory documents include anaphylactic reaction, hives, difficult breathing, or swelling of the face, lips, tongue, or throat.


Q: Does Aglaya affect liver function?

Aglaya is contraindicated (not to be used) in women with severe liver disease or liver tumors. Additionally, official warnings require the drug's use to be discontinued if jaundice (yellowing of the skin or eyes) develops.


Q: What are the most frequently reported side effects of Aglaya?

The most frequently reported adverse reactions listed in the official labeling include headache/migraine, nausea/vomiting, issues related to the breasts, and menstrual disorders.


Q: Is Aglaya known to affect sleep patterns?

Yes, insomnia and difficulty in sleeping are listed among the reported psychiatric and general adverse reactions in the official postmarketing experience section.


Q: Can Aglaya cause hair loss?

Alopecia (hair loss) is listed as a reported dermatologic side effect in the postmarketing experience section of the official prescribing information.


Q: What is the risk of accidental overdose with Aglaya?

Official drug information states that symptoms of overdose may include nausea and withdrawal vaginal bleeding.


Q: Can I use Aglaya with alcohol?

Official drug interaction listings classify the interaction between norgestimate/ethinyl estradiol and alcohol (ethanol) as minor. The classification does not include a severe restriction.


Q: Does Aglaya interact with common foods or drinks?

Yes, consumption of grapefruit or grapefruit juice is officially advised to be avoided or monitored. This is because it may increase the drug's plasma concentrations.


Q: Is there a warning about using Aglaya with tobacco products?

Yes, the drug carries a Boxed Warning stating that cigarette smoking increases the risk of serious cardiovascular events. For this reason, the drug is contraindicated in women over 35 years of age who smoke.


Q: Does Aglaya affect my ability to drive or use heavy machinery?

Reported neurological symptoms, such as dizziness and syncope (fainting), may potentially affect a patient’s ability to safely operate a vehicle or machinery.


Q: What happens if I forget to take a dose of Aglaya?

Official regulatory labeling provides detailed, specific instructions for managing missed doses. These procedures vary based on the number of missed tablets and which week of the cycle they were missed in.


Q: Is Aglaya safe for women over 50?

The drug is indicated for females of reproductive potential. Official documents note that appropriate studies on the relationship of age to the effects of this combination have generally not been performed in the geriatric population (women over 65).


Q: Can Aglaya be taken if I have kidney problems?

Renal impairment is listed as a condition where caution should be used. Unlike severe liver disease, it is generally not a contraindication unless certain complications, such as diabetes with vascular involvement, are present.


Q: Is there a risk of physical dependence or addiction with Aglaya?

The official FDA labeling for this combination hormonal contraceptive does not list any risk of abuse or physical dependence.


Q: Will Aglaya interfere with other hormone medications (e.g., thyroid)?

Yes, the estrogen component may alter thyroid-binding globulins and total thyroid hormone concentrations. This should be taken into account, as it may necessitate an increased dose of thyroid replacement therapy.


Q: Does Aglaya affect blood pressure?

The drug can cause a significant increase in blood pressure. For this reason, it is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease.


Q: What is the effect of Aglaya on blood sugar levels?

Official warnings note that the drug may have carbohydrate metabolic effects. The safety information advises that prediabetic and diabetic women should be monitored while using Aglaya.


Q: Is Aglaya a controlled substance?

No, Aglaya is a prescription drug but is not classified as a controlled substance by the DEA or other regulatory bodies.


Q: Can I use Aglaya while breastfeeding?

Breastfeeding is not recommended during use. Official labeling notes that the contraceptive hormones are present in human milk and can potentially reduce milk production.


Q: Is Aglaya safe to use for children under 15?

The drug is indicated for females at least 15 years of age who have achieved menarche (started having menstrual periods). Use before menarche is not indicated in the regulatory documents.


Q: Can men use Aglaya?

Official indications for Aglaya are for use by females of reproductive potential. The approved uses are for preventing pregnancy and treating moderate acne vulgaris in this population.


Q: What if I get sick (fever, flu) while on Aglaya?

If illness leads to vomiting or diarrhea within 3 to 4 hours of taking an active tablet, the drug may not work as effectively. Specific missed-dose instructions or the temporary use of a backup contraception method may apply.


Q: Does Aglaya interact with herbal supplements (e.g., St. John's Wort)?

The herbal product St. John's Wort may reduce the blood levels and effectiveness of the contraceptive. Official guidance advises that an alternative form of birth control may be needed if this supplement is used concurrently.


Q: Can I take Aglaya if I have a history of migraines?

Official regulatory documents state that Aglaya is contraindicated in women with migraines with aura, or in women over age 35 with any type of migraine.


Q: Does Aglaya work right away, or is a backup method needed?

Depending on the specific method used to initiate the first cycle (e.g., the Sunday Start method), an additional non-hormonal contraception may be necessary for the first seven days of the first cycle pack to ensure effective coverage.


Q: Is Aglaya a cure for acne?

The drug is officially indicated for the treatment of moderate acne vulgaris in certain females. It is approved for this use only if the patient also seeks an oral contraceptive for birth control.


Q: How should Aglaya be stored?

Official storage guidelines recommend that the drug be kept at room temperature, typically between 15 C and 30 C (59 F and 86 F). It should be protected from light and moisture and kept out of the reach of children.


Q: Can Aglaya be taken if I am trying to get pregnant soon?

The official guidance states that the drug’s use is discontinued if a patient is confirmed or suspects she may be pregnant. The drug is contraindicated for use in pregnancy.


Q: Does Aglaya affect fertility after stopping it?

Studies generally show that previous use of the pill does not impair long-term fertility. The ability to get pregnant is generally observed to return after discontinuation as the body adjusts back to its natural hormone cycles.


Q: Can Aglaya be taken if I have a history of depression?

Official safety information advises that women with a history of depression should have careful observation while using the medication. The guidance recommends to discontinue use if depression recurs to a serious degree.


Q: Does Aglaya affect the effectiveness of other medications I take?

Yes, the contraceptive steroids may influence the results of certain laboratory tests. Furthermore, they may affect the effectiveness of other medications, and an adjustment of doses for concurrent hormone replacement therapies may be required.


Q: Can Aglaya be taken at a different time each day?

Official dosing instructions recommend taking the tablet at the same time each day for consistency. This strict timing is important to maintain effective hormone levels for contraception.


Q: What happens if I use Aglaya during pregnancy?

The drug should be discontinued immediately during pregnancy. However, epidemiological data has generally not found an increased risk of birth defects from inadvertent exposure prior to conception or during early pregnancy.


Q: Can Aglaya be used for reasons other than contraception or acne?

The FDA-approved indications are solely for the prevention of pregnancy and the treatment of moderate acne vulgaris in eligible females. Use for other purposes is not addressed in official regulatory documents.


Q: Does Aglaya have a maximum duration of use?

There is no explicit maximum duration, but official warnings note risks associated with long-term use. These include an increased risk of developing liver tumors in users of greater than 8 years.


Q: Is there a rebound effect when stopping Aglaya?

After discontinuation, some patients may experience temporary side effects as the body adjusts to natural hormone levels. These effects can include irregular periods, acne flares, or mood changes.

How should Aglaya be stored and disposed of?

Aglaya (Ethinylestradiol and Norgestimate) must be stored under specific regulatory conditions to maintain stability.

Storage Requirements

Temperature and Protection: The tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Storage must avoid excessive heat and the product must be protected from moisture.

Container and Safety: Keep the medicine in its original, tightly closed container and store it out of the sight and reach of children and pets.


Disposal Instructions

Official Method: Unused or expired medication should primarily be disposed of through a drug take-back program.

Household Disposal: If a take-back option is unavailable, the medicine may be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a bag, and discarded in the household trash. This product must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aglaya found in:

A-Z Index: